Actinogen Medical Limited (ACW.AX)
AUD 0.03
(-6.9%)
AUD 0.03
(-6.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -9.13 Million AUD | -9.06% |
| 2023 | -8.37 Million AUD | 48.33% |
| 2022 | -16.2 Million AUD | -22.9% |
| 2021 | -13.18 Million AUD | -183.52% |
| 2020 | -4.65 Million AUD | 39.1% |
| 2019 | -7.63 Million AUD | 22.84% |
| 2018 | -9.89 Million AUD | -422.37% |
| 2017 | -1.89 Million AUD | -151.95% |
| 2016 | -751.97 Thousand AUD | 92.33% |
| 2015 | -9.8 Million AUD | -769.54% |
| 2014 | -1.12 Million AUD | -902.24% |
| 2013 | -112.51 Thousand AUD | 44.77% |
| 2012 | -203.73 Thousand AUD | 76.34% |
| 2011 | -861.18 Thousand AUD | 20.66% |
| 2010 | -1.08 Million AUD | 41.32% |
| 2009 | -1.84 Million AUD | 27.21% |
| 2008 | -2.54 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.42 Million AUD | 0.0% |
| 2024 Q4 | -9.13 Million AUD | 0.0% |
| 2024 FY | -9.13 Million AUD | -9.06% |
| 2023 Q4 | -8.37 Million AUD | 0.0% |
| 2023 FY | -8.37 Million AUD | 48.33% |
| 2023 Q2 | -14.35 Million AUD | 0.0% |
| 2022 Q2 | -22.02 Million AUD | 0.0% |
| 2022 FY | -16.2 Million AUD | -22.9% |
| 2022 Q4 | -16.2 Million AUD | 0.0% |
| 2021 Q2 | -12.56 Million AUD | 0.0% |
| 2021 FY | -13.18 Million AUD | -183.52% |
| 2021 Q4 | -13.18 Million AUD | 0.0% |
| 2020 Q2 | -8.02 Million AUD | 0.0% |
| 2020 FY | -4.65 Million AUD | 39.1% |
| 2020 Q4 | -4.65 Million AUD | 0.0% |
| 2019 FY | -7.63 Million AUD | 22.84% |
| 2019 Q2 | -15.46 Million AUD | 0.0% |
| 2019 Q4 | -7.63 Million AUD | 0.0% |
| 2018 Q4 | -9.89 Million AUD | 0.0% |
| 2018 FY | -9.89 Million AUD | -422.37% |
| 2018 Q2 | -4.41 Million AUD | 0.0% |
| 2017 Q2 | -2.59 Million AUD | 0.0% |
| 2017 Q4 | -1.89 Million AUD | 0.0% |
| 2017 FY | -1.89 Million AUD | -151.95% |
| 2016 FY | -751.97 Thousand AUD | 92.33% |
| 2016 Q4 | -751.97 Thousand AUD | 0.0% |
| 2016 Q2 | -2.7 Million AUD | 0.0% |
| 2015 Q4 | -9.8 Million AUD | 0.0% |
| 2015 Q2 | -2.05 Million AUD | 0.0% |
| 2015 FY | -9.8 Million AUD | -769.54% |
| 2014 Q2 | -1.35 Million AUD | 0.0% |
| 2014 Q4 | -1.12 Million AUD | 0.0% |
| 2014 FY | -1.12 Million AUD | -902.24% |
| 2013 Q4 | -112.51 Thousand AUD | 0.0% |
| 2013 Q2 | -296.84 Thousand AUD | 0.0% |
| 2013 Q1 | -296.84 Thousand AUD | -45.7% |
| 2013 FY | -112.51 Thousand AUD | 44.77% |
| 2013 Q3 | -112.51 Thousand AUD | 62.1% |
| 2012 FY | -203.73 Thousand AUD | 76.34% |
| 2012 Q4 | -203.73 Thousand AUD | 0.0% |
| 2011 FY | -861.18 Thousand AUD | 20.66% |
| 2011 Q4 | -861.18 Thousand AUD | 0.0% |
| 2010 Q4 | -1.08 Million AUD | 0.0% |
| 2010 FY | -1.08 Million AUD | 41.32% |
| 2009 FY | -1.84 Million AUD | 27.21% |
| 2009 Q4 | -1.84 Million AUD | 0.0% |
| 2008 Q4 | -2.54 Million AUD | 0.0% |
| 2008 FY | -2.54 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -980.449% |
| Acrux Limited | -1.45 Million AUD | -526.315% |
| Race Oncology Limited | -17.18 Million AUD | 46.874% |
| Biome Australia Limited | -1.56 Million AUD | -484.312% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 88.486% |
| BTC Health Limited | -2.02 Million AUD | -351.581% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -199.105% |
| CSL Limited | 15.76 Billion AUD | 100.058% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 93.31% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 95.01% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 51.681% |
| Hexima Limited | -2.22 Million AUD | -310.188% |
| Immutep Limited | -122.18 Million AUD | 92.527% |
| Memphasys Limited | 4.13 Million AUD | 320.818% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 46.58% |
| Noxopharm Limited | -2.31 Million AUD | -293.619% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 10.145% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 50.839% |
| Starpharma Holdings Limited | -19.83 Million AUD | 53.955% |
| Tissue Repair Ltd | -16.44 Million AUD | 44.458% |
| Biotron Limited | -386.06 Thousand AUD | -2265.3% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 26.829% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -829.804% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1186.951% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 280.207% |
| Patrys Limited | -2.24 Million AUD | -307.543% |
| Orthocell Limited | -19.92 Million AUD | 54.169% |
| Imugene Limited | -91.56 Million AUD | 90.027% |
| PYC Therapeutics Limited | -65.76 Million AUD | 86.114% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -44.4% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -47.156% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 28.179% |
| Nanollose Limited | -96.22 Thousand AUD | -9389.91% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -51.561% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -84.324% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -400.752% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -637.371% |
| Nyrada Inc. | -4.76 Million AUD | -91.465% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 91.368% |
| Dimerix Limited | -21.99 Million AUD | 58.477% |
| PharmAust Limited | -9.71 Million AUD | 5.996% |
| AnteoTech Limited | -5 Million AUD | -82.578% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 48.061% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -168.884% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -71.35% |
| Immuron Limited | -11.48 Million AUD | 20.482% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 42.614% |